News
Another innovative cancer project coordinated by the Celon Pharma S.A. Research and Development Centre has been launched
On 30 March this year the inaugural meeting was held for the research project: Development of modern biomarkers and development of an innovative FGFR kinase inhibitor for the treatment of neoplastic diseases – CELONKO; the meeting offered the project participants the chance to learn the main assumptions and current status of the project.
Celon Pharma hosts a meeting of the Polish Innovative Neuromedicine Platform
On 18 March Celon Pharma S.A. hosted another meeting of “InnoNeuroMed”, the Polish Innovative Neuromedicine Platform. The theme of the meeting was: different aspects of affective disorders. The meeting was attended by members of the Platform representing leading scientific institutions and pharmaceutical companies working in the field of neuromedicine in Poland.
Another innovative neurological research project carried out in Celon Pharma S.A. laboratories with support from the National Centre for Research and Development
The project entitled “New S-ketamine therapy for treatment-resistant depression” aims to develop a technology for a new route of ketamine administration in patients suffering from severe forms of treatment-resistant depression. Katamine is a well-known and widely used general anaesthetic. Recently, the possibility of its use in treatment of severe episodes of treatment-resistant depressionRead more »
Celon Pharma S.A. signed an agreement with Glemnark Pharmaceutical Europe Limited on commercialisation of Salmex into several European countries.
Celon Pharma S.A. signed an agreement with Glemnark Pharmaceutical Europe Limited on commercialisation of Salmex into several European countries. The company concluded an agreement under which it undertakes to, inter alia, supply a pharmaceutical product approved for marketing in selected European markets. The distribution agreement was concluded for a period of 10 years, with anRead more »
Celon Pharma S.A. and the National Science Centre supports young scientists
Celon Pharma S.A. recognised the most outstanding researcher in the field of life sciences by awarding a scholarship in a contest organised by the National Science Centre (NCN). The ceremony took place on 7 October 2015 in the Kraków Cloth Hall. The award was granted to Wiesław Babik PhD, whose outstanding achievements in the fieldRead more »
Celon Pharma S.A. research results on European Respiratory Society Congress
Celon Pharma S.A. researchers will attend ERS Annual Congress that will be held from 6th to 10th of September 2014 in Munich. We will take this opportunity to present the latest data on innovative small-molecule inhibitors of JAK/STAT pathway and PI3Kd kinase which are being developed in our laboratories as potential therapeutics for asthma andRead more »
Results of Celon Pharma S.A. research at the European Hematology Congress
The 19th Congress of the European Hematology Association, during which Celon Pharma S.A. will be presenting the latest results of research on developing innovative PI3K-delta inhibitors, will be held on 12-15 June in Milan. We wish to encourage participants to see our poster presentation entitled: “Preclinical evaluation of a novel highly potent and selective PI3K-deltaRead more »
A new publication from Celon Pharma S.A. laboratories!
Our new publication on experimental oncology has just appeared! The article entitled “Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma.” by Daria Zdzalik and co-workers was published in Journal of Cancer Research and Clinical Oncology and is freely available via PubMed/PMC.
We are presenting the results of our research at the ECC in Amsterdam
Celon Pharma S.A. will participate in The European Cancer Congress 2013, which will be held in Amsterdam, the Netherlands. We will be presenting two posters at a session which is taking place on 29 September 2013: “Epithelial-mesenchymal transition confers resistance to FGFR inhibitors in gastric cancer cell line” and “Design and development of active andRead more »